Gapping up
In reaction to earnings/guidance:
- SSYS +6.2%, NU +5.9%, QIPT +4.9%, HUYA +4.4%, PSFE +3.5%, DAC +3.4% (also appoints new COO), JHX +3%, LAC +1.5% (approves agreement providing for separation into two leading lithium companies), BIDU +1.2%, XP +1%, .
Other news:
- PX +6.3% (increases dividend)
- COF +6.3% (Warren Buffett discloses stake)
- BTAI +5.5% (Top-Line Data from Repeat Dosing of BXCL501 in Phase 1b Multiple Ascending Dose Trial)
- IMMP +5.2% (discloses it receives positive feedback from FDA on late-stage clinical development of eftilagimod alpha in non-small cell lung cancer)
- DISH +4.4% (Director bought 3000000 shares at $6.11 - $6.36 worth approx. $18.6 mln)
- CABA +4.4% (announces that the Company's second Investigational New Drug application for CABA-201 has been cleared by the U.S. FDA for a Phase 1/2 study)
- ROIV +3.6% (results from ADORING 1)
- IFRX +3.3% (InflaRx and Wuxi announce manufacturing partnership to advance Gohibic for the treatment of certain critically ill COVID-19 patients)
- NVTA +2.4% (appealing NTRA verdict)
- HPQ +1.7% (Warren Buffett increases stake)
- CUTR +1.5% (cancels special meeting)
- DEO +1.2% (Warren Buffett discloses stake)
Analyst comments:
- WAL +4% (resumed with a Buy at BofA Securities)
- FHN +3.9% (resumed with a Buy at BofA Securities)
- NVCR +3.6% (upgraded to Overweight from Equal Weight at Wells Fargo)
- DOX +2% (upgraded to Overweight from Equal Weight at Barclays)
- PLMR +1.5% (upgraded to Outperform from Mkt Perform at Keefe Bruyette)
- AMX +0.8% (upgraded to Buy from Neutral at New Street)
- GILD +0.8% (upgraded to Outperform from Market Perform at BMO Capital Markets)